Unicycive Therapeutics (NASDAQ:UNCY) Stock Rating Upgraded by Brookline Capital Management

Brookline Capital Management upgraded shares of Unicycive Therapeutics (NASDAQ:UNCY) to a strong-buy rating in a research note published on Tuesday morning, Zacks.com reports.

Other research analysts also recently issued reports about the company. HC Wainwright reiterated a buy rating and set a $4.50 target price on shares of Unicycive Therapeutics in a research report on Wednesday. Piper Sandler assumed coverage on Unicycive Therapeutics in a research report on Thursday, April 4th. They set an overweight rating and a $9.00 target price for the company. Finally, Benchmark reiterated a speculative buy rating and set a $3.00 target price on shares of Unicycive Therapeutics in a research report on Friday, May 31st. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of Buy and a consensus price target of $5.63.

Unicycive Therapeutics Price Performance

Shares of UNCY opened at $0.48 on Tuesday. Unicycive Therapeutics has a 1 year low of $0.34 and a 1 year high of $1.82. The company has a 50 day simple moving average of $0.78 and a two-hundred day simple moving average of $1.04. The firm has a market cap of $18.05 million, a P/E ratio of -0.40 and a beta of 2.39.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its earnings results on Monday, May 13th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.09). On average, sell-side analysts anticipate that Unicycive Therapeutics will post -0.82 earnings per share for the current year.

Institutional Trading of Unicycive Therapeutics

A number of institutional investors have recently bought and sold shares of UNCY. Rosalind Advisors Inc. bought a new stake in Unicycive Therapeutics in the first quarter worth $2,594,000. BVF Inc. IL increased its stake in Unicycive Therapeutics by 70.5% in the first quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock worth $4,984,000 after purchasing an additional 1,493,462 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Unicycive Therapeutics in the first quarter worth $36,000. 40.42% of the stock is currently owned by institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.